Multiple Sclerosis in Mongolia; the First Study Exploring Predictors of Disability and Depression in Mongolian MS Patients
暂无分享,去创建一个
Ikuo Tsunoda | Myadagmaa Jaalkhorol | Enkhsaruul Byambajav | Ana Bold | Oyunbileg Dulamsuren | N. Khaidav | Enkhdulguun Amgalan | Amarsaikhan Dashtseren | Badrangui Bat-Orgil | Anujin Chuluunbaatar | Nansalmaa Khaidav
[1] G. Trevisan,et al. Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis , 2022, Brain, behavior, & immunity - health.
[2] F. Mansuri,et al. Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia , 2022, Cureus.
[3] Basbish Tsogbadrakh,et al. Frontline Mongolian Healthcare Professionals and Adverse Mental Health Conditions During the Peak of COVID-19 Pandemic , 2022, Frontiers in Psychology.
[4] A. Martineau,et al. Prevalence and Determinants of Vitamin D Deficiency in 9595 Mongolian Schoolchildren: A Cross-Sectional Study , 2021, Nutrients.
[5] S. Hochmeister,et al. Vitamin D in Multiple Sclerosis—Lessons From Animal Studies , 2021, Frontiers in Neurology.
[6] Jiquan Chen,et al. How does mining policy affect rural migration of Mongolia? , 2021 .
[7] M. Moosazadeh,et al. Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis , 2021, AIMS neuroscience.
[8] J. Sellner,et al. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications , 2020, Journal of Neurology.
[9] V. Shaygannejad,et al. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis , 2020, Journal of clinical medicine.
[10] A. Vaitkus,et al. Clinical and diagnostic features of patients with familial multiple sclerosis. , 2019, Medical hypotheses.
[11] Sohila Khodakarim,et al. Determining the Levels of Urbanization in Iran Using Hierarchical Clustering , 2019, Iranian journal of public health.
[12] A. Ghezzi,et al. Aging with multiple sclerosis: prevalence and profile of cognitive impairment , 2019, Neurological Sciences.
[13] M. Ramanathan,et al. Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study , 2019, Journal of Neurology.
[14] J. Lechner-Scott,et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis , 2018, Multiple sclerosis.
[15] Narelle Warren,et al. Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease , 2018, Front. Neurol..
[16] Marjan Mansourian,et al. An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease , 2018, Journal of Neuroimmunology.
[17] J. Menzin,et al. Comorbidity in US patients with multiple sclerosis , 2018, Patient related outcome measures.
[18] Jorge R Oksenberg,et al. Multiple sclerosis genetics , 2018, Multiple sclerosis.
[19] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[20] Anders Larsson,et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.
[21] J. Lechner-Scott,et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.
[22] J. Haselkorn,et al. Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder , 2016, Current Neurology and Neuroscience Reports.
[23] M. Magyari. Gender differences in multiple sclerosis epidemiology and treatment response. , 2016, Danish medical journal.
[24] S. Morrow,et al. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. , 2015, Journal of affective disorders.
[25] Dashkovskiy Petr. Ethnic and Religious Processes in Western Mongolia (Based on Social Research) , 2015 .
[26] Jong-Jin Baik,et al. Characteristics of the urban heat island in a high-altitude metropolitan city, Ulaanbaatar, Mongolia , 2013, Asia-Pacific Journal of Atmospheric Sciences.
[27] G. Hallmans,et al. Smoking as a risk factor for multiple sclerosis , 2013, Multiple sclerosis.
[28] Kathleen F Villa,et al. The cost burden of multiple sclerosis in the United States: a systematic review of the literature , 2013, Journal of medical economics.
[29] W. Willett,et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. , 2012, The American journal of clinical nutrition.
[30] D. Hafler,et al. Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.
[31] M Daumer,et al. Age and disability accumulation in multiple sclerosis , 2011, Neurology.
[32] M. Filippi,et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[33] K. Dear,et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination , 2011, Neurology.
[34] Y.‐H. Chen,et al. Comorbidities amongst patients with multiple sclerosis: a population‐based controlled study , 2010, European journal of neurology.
[35] F. Guillemin,et al. Natural history of multiple sclerosis in a population‐based cohort , 2008, European journal of neurology.
[36] L. Nyström,et al. Smoking worsens the prognosis in multiple sclerosis , 2008, Multiple sclerosis.
[37] S. Ferrando,et al. Patient Health Questionnaire-9 to Screen for Depression in Outpatients With Multiple Sclerosis , 2007 .
[38] C. Pozzilli,et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.
[39] T. Pekmezović,et al. Lifestyle Factors and Multiple Sclerosis: A Case-Control Study in Belgrade , 2006, Neuroepidemiology.
[40] M. Melbye,et al. Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study. , 2006, Archives of neurology.
[41] Christian Confavreux,et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[42] D. Paty,et al. Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.
[43] R. Fujinami,et al. Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation , 2005, Journal of Neuroimmunology.
[44] L. Gunnarsson,et al. Quality of life and impairment in patients with multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[45] A. Ghezzi. Clinical characteristics of multiple sclerosis with early onset , 2004, Neurological Sciences.
[46] David R. Fraser,et al. Vitamin D-deficiency in Asia , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[47] Julián Benito-León,et al. A review about the impact of multiple sclerosis on health-related quality of life , 2003, Disability and rehabilitation.
[48] A. Janssens,et al. A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis , 2003, Multiple sclerosis.
[49] Maria Liguori,et al. Age‐related disability in multiple sclerosis , 2002, Annals of neurology.
[50] T. Sato,et al. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. , 2001, Psychosomatics.
[51] M. Amato,et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability , 2001, Multiple sclerosis.
[52] Lawrence Steinman,et al. Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.
[53] H. Suzuki,et al. Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. , 2000, The Journal of clinical psychiatry.
[54] B. Weinshenker,et al. Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.
[55] A. Stoudemire,et al. Corticosteroid-induced delirium and dependency. , 1996, General hospital psychiatry.
[56] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[57] T. Fog,et al. [Multiple sclerosis; review]. , 1954, Maanedsskrift for praktisk laegegerning og social Medicin.
[58] Erin L. Mazerolle,et al. Diabetes and anxiety adversely affect cognition in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.
[59] Sahana K.R,et al. Sunlight and vitamin D; A global perspective for health. , 2019 .
[60] M. Cohen,et al. [Depression in multiple sclerosis]. , 2009, Revue neurologique.
[61] Michelle Stern,et al. Aging with multiple sclerosis. , 2005, Physical medicine and rehabilitation clinics of North America.
[62] R. Spitzer,et al. The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.
[63] G. Lista. [The Babinski sign]. , 1966, Prensa Medica Argentina.